Jazz Pharmaceuticals
JAZZ
362 hedge funds and large institutions have $7.51B invested in Jazz Pharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 137 increasing their positions, 130 reducing their positions, and 53 closing their positions.
5% more repeat investments, than reductions
Existing positions increased: 137 | Existing positions reduced: 130
3% less funds holding
Funds holding: 374 → 362 (-12)
17% less first-time investments, than exits
New positions opened: 44 | Existing positions closed: 53
24% less capital invested
Capital invested by funds: $9.88B → $7.51B (-$2.37B)
46% less funds holding in top 10
Funds holding in top 10: 13 → 7 (-6)
47% less call options, than puts
Call options by funds: $51.8M | Put options by funds: $98.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$287M |
| 2 |
Fidelity International
Hamilton,
Bermuda
|
+$166M |
| 3 |
HCM
Herndon Capital Management
Atlanta,
Georgia
|
+$49.1M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$27.4M |
| 5 |
CCM
Cadian Capital Management
New York
|
+$26.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
PointState Capital
New York
|
-$98.4M |
| 2 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$96.5M |
| 3 |
HCM
Hoplite Capital Management
New York
|
-$49.9M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$49.6M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$38.4M |
JAZZ Hedge Fund Activity: Q3 2015 in Review
362 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q3 2015, worth a combined $7.51B — down 24% from $9.88B a quarter earlier.
Sellers outnumbered buyers: 53 funds closed out of JAZZ and 44 opened new positions — a net loss of 9 holders — while 130 trimmed existing stakes and 137 added.
The largest buyer was Putnam Investments, adding an estimated $287M. The largest seller was PointState Capital, cutting an estimated $98.4M.
- 362 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q3 2015, down from 374 in Q2 2015.
- Funds reported $7.51B of Jazz Pharmaceuticals stock for Q3 2015, down 24% quarter-over-quarter.
- 44 funds opened new Jazz Pharmaceuticals positions in Q3 2015 and 53 closed out, a net change of -9 holders.
- The largest Jazz Pharmaceuticals buyer in Q3 2015 was Putnam Investments, an estimated $287M added.
- The largest Jazz Pharmaceuticals seller in Q3 2015 was PointState Capital, an estimated $98.4M sold.
Based on aggregated 13F filings for Q3 2015.